These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 19554396

  • 1. Tocilizumab is effective for pulmonary hypertension associated with multicentric Castleman's disease.
    Taniguchi K, Shimazaki C, Fujimoto Y, Shimura K, Uchiyama H, Matsumoto Y, Kuroda J, Horiike S, Taniwaki M.
    Int J Hematol; 2009 Jul; 90(1):99-102. PubMed ID: 19554396
    [Abstract] [Full Text] [Related]

  • 2. The efficacy of tocilizumab in a patient with pulmonary arterial hypertension associated with Castleman's disease.
    Arita Y, Sakata Y, Sudo T, Maeda T, Matsuoka K, Tamai K, Higuchi K, Shioyama W, Nakaoka Y, Kanakura Y, Yamauchi-Takihara K.
    Heart Vessels; 2010 Sep; 25(5):444-7. PubMed ID: 20676969
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Membranous nephropathy associated with multicentric Castleman's disease that was successfully treated with tocilizumab: a case report and review of the literature.
    Saiki R, Katayama K, Hirabayashi Y, Oda K, Fujimoto M, Murata T, Nakajima A, Dohi K.
    BMC Nephrol; 2021 Jun 09; 22(1):216. PubMed ID: 34107915
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Interleukin-6 in idiopathic multicentric Castleman's disease after long-term tocilizumab.
    Akiyama M, Yasuoka H, Takeuchi T.
    Ann Hematol; 2017 Dec 09; 96(12):2117-2119. PubMed ID: 28861599
    [No Abstract] [Full Text] [Related]

  • 7. Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease.
    Kawabata H, Tomosugi N, Kanda J, Tanaka Y, Yoshizaki K, Uchiyama T.
    Haematologica; 2007 Jun 09; 92(6):857-8. PubMed ID: 17550864
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A comorbid case of multicentric Castleman's disease and pulmonary hyalinising granuloma successfully treated with tocilizumab and corticosteroid.
    Takeuchi N, Arai T, Kitaichi M, Inoue Y.
    BMJ Case Rep; 2013 Sep 26; 2013():. PubMed ID: 24072826
    [Abstract] [Full Text] [Related]

  • 11. A case of multicentric Castleman's disease having lung lesion successfully treated with humanized anti-interleukin-6 receptor antibody, tocilizumab.
    Higuchi T, Nakanishi T, Takada K, Matsumoto M, Okada M, Horikoshi H, Suzuki K.
    J Korean Med Sci; 2010 Sep 26; 25(9):1364-7. PubMed ID: 20808682
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The Role of Interleukin-6 in Castleman Disease.
    Yoshizaki K, Murayama S, Ito H, Koga T.
    Hematol Oncol Clin North Am; 2018 Feb 26; 32(1):23-36. PubMed ID: 29157617
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Multicentric Castleman's disease associated with IgA vasculitis (Henoch-Schönlein purpura) responding well to tocilizumab: a case report.
    Oshima Y, Hoshino J, Suwabe T, Hayami N, Yamanouchi M, Sekine A, Ueno T, Mizuno H, Yabuuchi J, Imafuku A, Kawada M, Hiramatsu R, Hasegawa E, Sawa N, Takaichi K, Hayashi N, Fujii T, Ubara Y.
    Clin Rheumatol; 2017 Mar 26; 36(3):729-733. PubMed ID: 28168662
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Multicentric Castleman's disease associated with glomerular microangiopathy and MPGN-like lesion: does vascular endothelial cell-derived growth factor play causative or protective roles in renal injury?
    Seida A, Wada J, Morita Y, Baba M, Eguchi J, Nishimoto N, Okino T, Ichimura K, Yoshino T, Makino H.
    Am J Kidney Dis; 2004 Jan 26; 43(1):E3-9. PubMed ID: 14712466
    [Abstract] [Full Text] [Related]

  • 19. [Tocilizumab treatment of HHV8-positive/HIV-negative, multricentric plasma cell type Castleman's disease].
    Mûzes G, Csomor J, Sipos F.
    Magy Onkol; 2016 Nov 29; 60(4):328-332. PubMed ID: 27898752
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.